

12-9-2015

Impact of Donor Lung Gram Stain on Post-Transplant Pneumonia and Mortality: More Lungs Can Be Used to Save Lives

Sher Ali Khan

University of California - San Diego

Emir Veledar

Department of Biostatistics, Florida International University, eveledar@fiu.edu

Cathy Logan

University of California - San Diego

Sanjay Mehta

University of California - San Diego

Gordon Yung

University of California - San Diego

See next page for additional authors

Follow this and additional works at: https://digitalcommons.fiu.edu/biostatistics_fac

 Part of the [Medicine and Health Sciences Commons](#)

Recommended Citation

Khan, Sher Ali; Veledar, Emir; Logan, Cathy; Mehta, Sanjay; Yung, Gordon; and Aslam, Saima, "Impact of Donor Lung Gram Stain on Post-Transplant Pneumonia and Mortality: More Lungs Can Be Used to Save Lives" (2015). *Department of Biostatistics Faculty Publications*. 28.

https://digitalcommons.fiu.edu/biostatistics_fac/28

This work is brought to you for free and open access by the Robert Stempel College of Public Health & Social Work at FIU Digital Commons. It has been accepted for inclusion in Department of Biostatistics Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.

Authors

Sher Ali Khan, Emir Veledar, Cathy Logan, Sanjay Mehta, Gordon Yung, and Saima Aslam

1223. Impact of Donor Lung Gram Stain on Post-Transplant Pneumonia and Mortality: More Lungs Can Be Used to Save Lives

Sher Ali Khan, MBBS¹; Emir Veledar, PhD²; Cathy Logan, MD³; Sanjay Mehta, MD⁴; Gordon Yung, MD³; Saima Aslam, MD, MS⁵; ¹Medicine, UC San Diego, San Diego, California; ²Florida International University, Miami, Florida; ³UC San Diego, San Diego, California; ⁴Medicine, University of California, San Diego, La Jolla, California; ⁵Division of Infectious Disease, University of California, San Diego, La Jolla, California

Session: 158. Transplant Screenings and Evaluation and Empiric and Pre-Emptive Therapy


Friday, October 9, 2015: 12:30 PM

Background. Donor lungs with Gram-stain (GS) evidence of bacteria on bronchoscopy specimens are considered infected and generally deemed unsuitable for transplant. We sought to assess the impact of donor lung GS on the occurrence of post-transplant pneumonia (PTP), length of stay (LOS), and mortality.

Methods. We retrospectively reviewed medical records of all lung transplant recipients (LTR) at our center from December 2004 to February 2014. PTP was defined by the presence of at least 2 of 3 criteria that occurred within 30 days of transplant: (1) symptoms, signs or laboratory markers consistent with pneumonia; (2) radiological evidence; and (3) positive respiratory culture. Statistics: Univariate and multivariate analyses, Kaplan-Meier (KM) curves, and log-rank test.

Results. Among 149 LTRs, 45 received donor lungs with GS positive for bacteria at the time of implantation (GS+ group) and 104 received lungs with GS negative for bacteria (GS- group). Standard immunosuppression consisted of tacrolimus, mycophenolate mofetil and steroids; induction with basiliximab was rarely used. GS+ recipients spent longer time on the wait-list (mean 416.6 versus 230.6 days, $p = 0.007$) and were more likely to have a double lung transplant (80% versus 59.6%, $p = 0.02$) but were otherwise similar at baseline. Receipt of GS+ lungs was associated with longer post-operative ventilator time (mean 277.4 versus 77.1 hours, $p = 0.045$), along with prolonged intensive care unit (ICU) and overall LOS (mean 15.9 versus 9.5 days, $p = 0.014$; mean 36.2 versus 21.7 days, $p = 0.005$, respectively). Rate of PTP was similar in both groups (51% versus 38.5%, $p = 0.21$) as was overall mortality (31.1% versus

35.6%, $p = 0.71$) with similar KM curves (figure, log-rank $p = 0.2$). In multivariate analysis, GS+ group remained an independent predictor of ICU stay (OR 5.9, 95% CI 1.1-10.7, $p = 0.016$) and LOS (OR 12.6, 95% CI 2.9-22.3, $p = 0.01$).



Conclusion. Use of donor lungs that are Gram-stain positive for bacteria is associated with longer time on the ventilator, and in the ICU and hospital. However, it does not impact the development of pneumonia in the first 30 days post-transplant or mortality. Hence, criteria for use of donor lungs should be liberalized with the potential to save more lives.

Disclosures. All authors: No reported disclosures.